Juan Harrison

Mr. Juan Harrison is a biotechnology and pharmaceutical executive focused on company formation, strategy, partnering, venture investment and licensing transactions. He is currently providing advisory services to several early stage companies, venture capital enterprises and academic centers. He was previously Vice President and Head of Strategic Academic Alliances at Takeda Pharmaceuticals where he was responsible for establishing several broad drug discovery alliances, including the Tri-Institutional Therapeutics Discovery Institute (Weill Cornell Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center), the Alliance for Innovative Medicines (Stanford University), the Seattle Partnership for Research in Innovative Therapeutics (SPRInT, including the Fred Hutchinson Cancer Research Center, the University of Washington, and Seattle Children’s Hospital), and the Dana Farber Cancer Institute. Before leading Takeda’s SAA, he was VP at Takeda Ventures where he invested in several companies including Envoy Therapeutics, later acquired by Takeda. Mr. Harrison has been working in the biopharmaceutical industry since 1985 and has held senior positions in Alza Pharmaceuticals, Connetics, PowderJect and XenoPort. He received a BS in Combined Science from Santa Clara University with emphasis in Chemistry and Biochemistry.